Eli Muchtar

Hematology

200 1st St SW
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 290 publications

Reply: Biochemical Remission and Residual Cardiac Abnormalities in AL Amyloidosis.

Reply: Biochemical Remission and Residual Cardiac Abnormalities in AL Amyloidosis.

Journal: JACC. CardioOncology

Published: June 28, 2026

Crescentic Glomerulonephritis in a Patient With AL Amyloidosis: A Case Report.

Crescentic Glomerulonephritis in a Patient With AL Amyloidosis: A Case Report.

Journal: Kidney medicine

Published: June 01, 2026

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Journal: American journal of hematology

Published: May 30, 2026

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Journal: Research square

Published: April 17, 2026

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Journal: Blood advances

Published: April 07, 2026

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Journal: Blood advances

Published: April 07, 2026

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Journal: American journal of hematology

Published: March 31, 2026

Immune Effector Cell-Associated Enterocolitis Reporting with BCMA- and CD19-Directed Immune Cell Therapies.

Immune Effector Cell-Associated Enterocolitis Reporting with BCMA- and CD19-Directed Immune Cell Therapies.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: March 28, 2026

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

Journal: British journal of haematology

Published: March 23, 2026

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Journal: American journal of hematology

Published: March 17, 2026

A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.

A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.

Journal: JACC. CardioOncology

Published: March 16, 2026

Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

Journal: Blood advances

Published: March 06, 2026

Showing 1-12 of 290

Last Updated: 09/26/2026